These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10550454)

  • 1. Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.
    Cooper C; Stakkestad JA; Radowicki S; Hardy P; Pilate C; Dain MP; Delmas PD
    Osteoporos Int; 1999; 9(4):358-66. PubMed ID: 10550454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group.
    Delmas PD; Pornel B; Felsenberg D; Garnero P; Hardy P; Pilate C; Dain MP
    Bone; 1999 May; 24(5):517-23. PubMed ID: 10321913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women.
    Delmas PD; Pornel B; Felsenberg D; Stakkestad JA; Radowicki S; Garnero P; Hardy P; Dain MP; Petitier B;
    Am J Obstet Gynecol; 2001 Jan; 184(2):32-40. PubMed ID: 11174476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial.
    Arrenbrecht S; Boermans AJ
    Osteoporos Int; 2002; 13(2):176-83. PubMed ID: 11908492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoporosis prevention clinical study program.
    Delmas P; Gimona A
    Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S39-45. PubMed ID: 8732473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.
    Bhattoa HP; Bettembuk P; Balogh A; Szegedi G; Kiss E
    Osteoporos Int; 2004 May; 15(5):396-404. PubMed ID: 14676992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
    Warming L; Ravn P; Christiansen C
    Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
    Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
    Stakkestad JA; Benevolenskaya LI; Stepan JJ; Skag A; Nordby A; Oefjord E; Burdeska A; Jonkanski I; Mahoney P;
    Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis.
    Warming L; Ravn P; Nielsen T; Christiansen C
    Climacteric; 2004 Mar; 7(1):103-11. PubMed ID: 15259289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study.
    Nielsen TF; Ravn P; Bagger YZ; Warming L; Christiansen C
    Osteoporos Int; 2004 Feb; 15(2):168-74. PubMed ID: 14647880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group.
    Weiss SR; Ellman H; Dolker M
    Obstet Gynecol; 1999 Sep; 94(3):330-6. PubMed ID: 10472854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of 17beta-estradiol at doses of 0.5, 1 and 2 mg compared with placebo on early postmenopausal bone loss in hysterectomized women.
    Giske LE; Hall G; Rud T; Landgren BM
    Osteoporos Int; 2002; 13(4):309-16. PubMed ID: 12030546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women.
    Stevenson JC; Teter P; Lees B
    Maturitas; 2001 Apr; 38(2):197-203. PubMed ID: 11306209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral weekly ibandronate prevents bone loss in postmenopausal women.
    Tankó LB; Felsenberg D; Czerwiński E; Burdeska A; Jonkanski I; Hughes C; Christiansen C;
    J Intern Med; 2003 Aug; 254(2):159-67. PubMed ID: 12859697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women.
    Rubinacci A; Peruzzi E; Modena AB; Zanardi E; Andrei B; De Leo V; Pansini FS; Quebe-Fehling E; de Palacios PI
    Menopause; 2003; 10(3):241-9. PubMed ID: 12792297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.